BioCentury
ARTICLE | Clinical News

MTR106: Phase II data

November 12, 2007 8:00 AM UTC

In a double-blind, placebo-controlled Phase II trial in 40 female patients with migraine without aura, all 4 doses of MTR106 (25, 50, 75 and 100 mg) met the primary endpoint of superiority to placebo ...